Peter R. Gibson

Peter R. Gibson

Auto-generated profile, based on publicly available information

Peter R. Gibson

Department of Gastroenterology, School of Translational Medicine Monash University Melbourne Victoria Australia

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2018 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
PGPaul Gill
Paul Gill
MZM. C. van Zelm
M. C. van Zelm
JMJane Muir
Jane Muir
PGP. R. Gibson
P. R. Gibson

8 January 2018 in Nature Electronics
Verified
Journal Article
Closed access
PDF file
KKKourosh Kalantar-Zadeh
Kourosh Kalantar-Zadeh
KBKyle J. Berean
Kyle J. Berean
NHNam Ha
Nam Ha
ACAdam F. Chrimes
Adam F. Chrimes
KXKai Xu
Kai Xu
PGPeter R. Gibson
Peter R. Gibson

13 September 2019 in Nature Reviews Gastroenterology & Hepatology
Verified
Journal Article
Closed access
PDF file
KKKourosh Kalantar-Zadeh
Kourosh Kalantar-Zadeh
KBKyle J. Berean
Kyle J. Berean
RBRebecca E. Burgell
Rebecca E. Burgell
JMJane G. Muir
Jane G. Muir
PGPeter R. Gibson
Peter R. Gibson

13 August 2019 in Gut
Verified
Journal Article
Closed access
PDF file
MGMayur Garg
Mayur Garg
SRSimon G Royce
Simon G Royce
CTChris Tikellis
Chris Tikellis
CSClaire Shallue
Claire Shallue
DBDuygu Batu
Duygu Batu
JLJohn Lubel
John Lubel
Objective We evaluated the influence of the renin–angiotensin system (RAS) on intestinal inflammation and fibrosis. Design Cultured human colonic myofibroblast proliferation and collagen secretion were assessed following treatment with angiotensin (Ang) II and Ang (1–7), their receptor antagonists candesartan and A779, and the ACE inhibitor captopril. Circulating and intestinal RAS components were evaluated in patients with and without IBD. Disease outcomes in patients with IBD treated with ACE inhibitors and angiotensin receptor blockers (ARBs) were assessed in retrospective studies. Results Human colonic myofibroblast proliferation was reduced by Ang (1–7) in a dose-dependent manner (p<0.05). Ang II marginally but not significantly increased proliferation, an effect reversed by candesartan (p<0.001). Colonic myofibroblast collagen secretion was reduced by Ang (1–7) (p<0.05) and captopril (p<0.001), and was increased by Ang II (p<0.001). Patients with IBD had higher circulating renin (mean 25.4 vs 18.6 mIU/L, p=0.026) and ACE2:ACE ratio (mean 0.92 vs 0.69, p=0.015) than controls without IBD. RAS gene transcripts and peptides were identified in healthy and diseased bowels. Colonic mucosal Masson’s trichrome staining correlated with Ang II (r=0.346, p=0.010) and inversely with ACE2 activity (r=−0.373, p=0.006). Patients with IBD who required surgery (1/37 vs 12/75, p=0.034) and hospitalisation (0/34 vs 8/68, p=0.049) over 2 years were less often treated with ACE inhibitors and ARBs than patients not requiring surgery or hospitalisation. Conclusions The RAS mediates fibrosis in human cell cultures, is expressed in the intestine and perturbed in intestinal inflammation, and agents targeting this system are associated with improved disease outcomes.

1 April 2016 in Clinical and Translational Gastroenterology
Verified
Journal Article
Open access
EHEmma P. Halmos
Emma P. Halmos
CCClaus Christophersen
Claus Christophersen
ABAnthony R Bird
Anthony R Bird
SSSusan J Shepherd
Susan J Shepherd
JMJane G Muir
Jane G Muir
PGPeter R Gibson
Peter R Gibson
OBJECTIVES:Altering FODMAP (fermentable oligosaccharides, disaccharides, monosaccharides and polyols) intake has substantial effects on gut microbiota. This study aimed to investigate effects of altering FODMAP intake on markers of colonic health in patients with Crohn's disease.METHODS:After evalua

1 May 2015 in Gastroenterology
Verified
Journal Article
Closed access
PGPeter R. Gibson
Peter R. Gibson
JVJane Varney
Jane Varney
SMSreepurna Malakar
Sreepurna Malakar
JMJane G. Muir
Jane G. Muir